{"entity":{"id":"nct07721259","kind":"trial","name":"A Vaccine (STEMVAC) for Improving Survival in Patients With Triple-Negative Breast Cancer and Moderate or Extensive Residual Cancer Burden","aka":["STEMVAC"],"tldr":"A phase 2 trial in triple-negative breast cancer, run by University of Washington, not yet recruiting.","summary":"A Vaccine (STEMVAC) for Improving Survival in Patients With Triple-Negative Breast Cancer and Moderate or Extensive Residual Cancer Burden is a phase 2, randomised interventional study registered as NCT07721259 by University of Washington, with a registry enrolment figure of 60 participants, started 2026-09-30 and due to reach its primary completion in 2029-07-16. Interventions recorded: CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine; Recombinant Granulocyte-Macrophage Colony-Stimulating Factor; Biospecimen Collection. Conditions listed: Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Triple-Negative Breast Carcinoma. Triple-negative eligibility wording from the registry: \"* Triple-negative breast cancer as determined by the treating oncologist\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07721259","url":"https://clinicaltrials.gov/study/NCT07721259"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-early"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07721259","phase":"2","setting":"A Multiantigen Vaccine (STEMVAC) for Adjuvant Treatment of Patients With Moderate or Extensive Residual Triple-Negative Breast Cancer","sponsor":"University of Washington","participation":[{"nct":"NCT07721259","source":"https://clinicaltrials.gov/study/NCT07721259","fetchedAt":"2026-10-07T16:56:10.647Z","studySha256":"51ec4036aaa4debc8bbe003468ed56ad8f056ddc2e52e0c4a345be49160fa614","overallStatus":"NOT_YET_RECRUITING","lastUpdatePosted":"2026-07-23","leadSponsor":"University of Washington","collaboratorCount":1,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":60,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":0,"countries":["United States"]}],"started":"2026-09-30","startedType":"estimated","enrolled":60,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07721259/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}